Evaluating the Use of 18F-FDG PET CT for External Beam Radiotherapy Planning in Gynaecological Malignancies
Purpose of Review
To evaluate the evidence for the use of fluorine-18-fluorodeoyglucose (18F-FDG) PET CT in external beam radiotherapy planning for treatment of gynaecological malignancies.
Our review confirms that the incorporation of 18F-FDG PET CT during radiotherapy planning may decrease inter-observer variability during target delineation. It can also provide useful functional information regarding the tumour, which may facilitate the development of techniques for dose escalation and ‘dose painting’ not only for primary disease, especially in cervical cancer, but also nodal metastasis.
The utilisation of this functional modality in external beam radiotherapy planning, particularly in locally advanced cervical malignancy, is an exciting topic that warrants further prospective research. Perhaps the most valuable role may be the potential to deliver dose escalation to 18F-FDG PET CT avid targets previously limited by organ at risk constraints, now that we have significantly more advanced radiotherapy planning tools at our disposal.
KeywordsRadiotherapy planning Cervical cancer PET CT Gynaecological malignancies EBRT
Compliance with Ethical Standards
Conflict of Interest
Ashleigh Kerr, Nicholas Reed, Rosie Harrand, Kathryn Graham, and Azmat H. Sadozye declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 9.Sugwara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med. 1999;40(7):1125–31.Google Scholar
- 11.Management of cervical cancer: a national clinical guideline [Internet]. Scottish Intercollegiate Guidelines Network; 2008 [cited 2 February 2018]. Available from: http://www.sign.ac.uk/assets/sign99.pdf.
- 12.Scottish Cancer Task Force. Cervical cancer: clinical quality performance indicators [Internet]. Health Care Improvement Scotland; 2016 [cited 3 March 2018]. Available from: http://healthcareimprovementscotland.org/his/idoc.ashx?docid=d48b66ab-c7f0...1.
- 13.Caldwell CB, Mah K, Ung YC, Danjoux CE, Balogh JM, Ganguli SN, et al. Observer variation in contouring gross tumour volume in patients with poorly defined non-small-cell lung tumours on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923–31.CrossRefPubMedGoogle Scholar
- 18.Upasani M, Mahantshetty U, Rangarajan V, Purandare N, Merchant N, Thakur M, et al. 18-Fluoro-deoxy-glucose positron emission tomography with computed tomography–based gross tumor volume estimation and validation with magnetic resonance imaging for locally advanced cervical cancers. Int J Gynecol Cancer. 2012;22(6):1031–6.CrossRefPubMedGoogle Scholar
- 19.• Arnesen M, Rekstad B, Stokke C, Bruheim K, Løndalen A, Hellebust T, et al. Short-course PET based simultaneous integrated boost for locally advanced cervical cancer. Radiat Oncol. 2016;11(1):39. Authors have demonstrated how PET CT integrated into planning could be utilized for dose escalation/dose painting. CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Lazzari R, Cecconi A, Jereczek-Fossa B, Travaini L, Dell’Acqua V, Cattani F, et al. The role of 18F FDG-PET/CT in staging and treatment planning for volumetric modulated Rapidarc radiotherapy in cervical cancer: experience of the European Institute of Oncology, Milan, Italy. Ecancermedicalscience. 2014;8:405.PubMedGoogle Scholar
- 22.• Chung Y, Horng C, Lee P, Chen F. Patterns of failure after use of 18F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases. BMC Cancer. 2016;16(1):179. Provides evidence to support that dose escalation based on PET CT-integrated planning is deliverable and generates the hypothesis that such dose escalation may be clinically meaningful. CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Small W, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68(4):1081–7.CrossRefPubMedGoogle Scholar
- 25.Cihoric N, Tapia C, Krüger K, Aebersold D, Klaeser B, Lössl K. IMRT with 18FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer. Radiat Oncol [Internet]. 2014 [cited 2 February 2018];9(1):83. Available from: http://www.ro-journal.com/content/9/1/83.CrossRefPubMedGoogle Scholar
- 26.• Esthappan J, Chaudhari S, Santanam L, Mutic S, Olsen J, MacDonald D, et al. Prospective clinical trial of positron emission tomography/computed tomography image-guided intensity-modulated radiation therapy for cervical carcinoma with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2008;72(4):1134–9. One of the earlier studies confirming the feasibility of using PET CT-integrated planning for dose escalation. CrossRefPubMedGoogle Scholar
- 27.Vees H, Casanova N, Zilli T, Imperiano H, Ratib O, Popowski Y et al. Impact of 18F-FDG PET/CT on target volume delineation in recurrent or residual gynaecologic carcinoma. Radiat Oncol [Internet]. 2012 [cited 2 February 2018];7(1):176. Available from: http://www.ro-journal.com/content/7/1/176.CrossRefPubMedGoogle Scholar
- 28.de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295–309.CrossRefPubMedPubMedCentralGoogle Scholar